MX2019003457A - Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo. - Google Patents

Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo.

Info

Publication number
MX2019003457A
MX2019003457A MX2019003457A MX2019003457A MX2019003457A MX 2019003457 A MX2019003457 A MX 2019003457A MX 2019003457 A MX2019003457 A MX 2019003457A MX 2019003457 A MX2019003457 A MX 2019003457A MX 2019003457 A MX2019003457 A MX 2019003457A
Authority
MX
Mexico
Prior art keywords
manufacturing
application
same
composition
rxr
Prior art date
Application number
MX2019003457A
Other languages
English (en)
Inventor
Li Zhibin
Yu Jindi
Pan Desi
Shan Song
Lu Xianping
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of MX2019003457A publication Critical patent/MX2019003457A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención desvela un compuesto enantiomérico de ácido (-)-2- [(2-(4-fluorobenzoil)fenil)amino]-3-[(4-(2-carbazol-etoxi) fenil)]propiónico como se representa mediante la fórmula (I), o una sal farmacéuticamente aceptable del mismo, y un método de fabricación del compuesto y aplicación del mismo. El compuesto enantiomérico demuestra una activación relativamente mejor de expresión de heterodímeros de RXR/PPAR, RXR/PPAR y RXR/PPAR y reducción de azúcar en un modelo de ratón db/db en comparación con un enantiómero (+)-. (ver fórmula).
MX2019003457A 2016-09-27 2017-09-27 Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo. MX2019003457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610856914.7A CN107868032B (zh) 2016-09-27 2016-09-27 一种取代的苯基丙酸化合物对映异构体及其制备方法、组合物和应用
PCT/CN2017/103619 WO2018059428A1 (zh) 2016-09-27 2017-09-27 一种取代的苯基丙酸化合物对映异构体及其制备方法、组合物和应用

Publications (1)

Publication Number Publication Date
MX2019003457A true MX2019003457A (es) 2019-10-15

Family

ID=61751426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003457A MX2019003457A (es) 2016-09-27 2017-09-27 Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo.

Country Status (12)

Country Link
US (1) US20200031771A1 (es)
EP (1) EP3521275A4 (es)
JP (1) JP6887014B2 (es)
KR (1) KR20190053263A (es)
CN (2) CN112479977B (es)
AU (1) AU2017333055B2 (es)
BR (1) BR112019005980A2 (es)
CA (1) CA3038382C (es)
MX (1) MX2019003457A (es)
RU (1) RU2735524C2 (es)
TW (1) TWI729218B (es)
WO (1) WO2018059428A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US743438A (en) * 1903-01-02 1903-11-10 Otto Boers Sheep-shears.
RU2342362C2 (ru) * 2002-11-26 2008-12-27 Шэньчжэнь Чипскрин Байосайенсиз Лтд. Замещенные производные арилалкановой кислоты как пан агонисты рапп с высокой антигипергликемической и антигиперлипидемической активностью
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
CN1257893C (zh) * 2003-06-17 2006-05-31 深圳微芯生物科技有限责任公司 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂
WO2005075974A1 (ja) * 2004-02-03 2005-08-18 Daicel Chemical Industries, Ltd. 超臨界流体クロマトグラフィーによって光学異性体を分離する方法
CN103382185B (zh) * 2013-07-02 2016-02-24 常州大学 6,12-二苯基二苯并[b,f][1,5]二氮杂环辛四烯的手性制备及构型确定
CN105801468B (zh) * 2014-12-31 2018-08-17 深圳微芯生物科技股份有限公司 一种苯丙氨酸类化合物的盐及其无定形体
CN104744282A (zh) * 2015-02-17 2015-07-01 南通恒盛精细化工有限公司 一种胰岛素增敏剂的制备工艺
CN107868033B (zh) * 2016-09-27 2021-05-18 深圳微芯生物科技股份有限公司 一种苯丙氨酸类化合物的制备方法

Also Published As

Publication number Publication date
CN112479977A (zh) 2021-03-12
CA3038382C (en) 2021-06-01
RU2735524C2 (ru) 2020-11-03
EP3521275A4 (en) 2020-03-25
CN107868032A (zh) 2018-04-03
RU2019112450A (ru) 2020-10-29
TW201813955A (zh) 2018-04-16
JP2019529503A (ja) 2019-10-17
US20200031771A1 (en) 2020-01-30
BR112019005980A2 (pt) 2019-06-18
AU2017333055A1 (en) 2019-05-02
EP3521275A1 (en) 2019-08-07
KR20190053263A (ko) 2019-05-17
AU2017333055B2 (en) 2020-07-16
RU2019112450A3 (es) 2020-10-29
CA3038382A1 (en) 2018-04-05
JP6887014B2 (ja) 2021-06-16
TWI729218B (zh) 2021-06-01
WO2018059428A1 (zh) 2018-04-05
CN107868032B (zh) 2020-12-15
CN112479977B (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
PH12020552187A1 (en) Pcsk9 antagonist compounds
TN2018000319A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
UA109547C2 (uk) Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин
PH12017501171A1 (en) 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one as a seed treatment
PH12018501543A1 (en) Fungicidal composition
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
IL275585A (en) A process for separating enantiomers of nicotine from a serial mixture
MX2018000050A (es) Fenoxihalogenofenilamidinas y su uso como fungicidas.
NZ728529A (en) Fused 11-membered compounds and agricultural/horticultural fungicides containing them
MX2018001205A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.
EA202092620A1 (ru) Соли и твердые формы монобактамного антибиотика
MX2018001204A (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido.
NZ721645A (en) Compounds for use as gpr120 agonists
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
EP2987791A4 (en) NOVEL 3- (4- (BENZYLOXY) PHENYL) HEX-4-INOIC ACID DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING IT AS AN EFFECTIVE INGREDIENT
PH12016501327A1 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
EA201891437A1 (ru) Способ разделения энантиомеров пиперазиновых производных
MY179951A (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MX2019003457A (es) Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo.
UA105640C2 (uk) Співкристал пропіконазолу і карбонової кислоти, фунгіцидна композиція на його основі і спосіб контролю грибного інфікування рослин
WO2016044918A8 (en) Processes for the preparation of rotigotine and intermediates thereof
BR112019006371A2 (pt) compostos, composições farmacêuticas, uso de um composto ou composição e kits
MX2019000442A (es) Derivados de etinilo.
WO2017094031A3 (en) Novel process for preparation of apremilast